Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antimetabolites"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 61-80 z 7517
Tytuł:
Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease.
Autorzy:
Kawakami, Hisato (AUTHOR)
Nishikawa, Kazuhiro (AUTHOR)
Shimokawa, Toshio (AUTHOR)
Fujitani, Kazumasa (AUTHOR)
Tamura, Shigeyuki (AUTHOR)
Endo, Shunji (AUTHOR)
Kobayashi, Michiya (AUTHOR)
Kawada, Junji (AUTHOR)
Kurokawa, Yukinori (AUTHOR)
Tsuburaya, Akira (AUTHOR)
Yoshikawa, Takaki (AUTHOR)
Sakamoto, Junichi (AUTHOR)
Satoh, Taroh (AUTHOR)
Pokaż więcej
Źródło:
Cancers. Nov2022, Vol. 14 Issue 22, p5673. 13p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.
Autorzy:
Huschart E; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
Miller H; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.; Mayo Clinic Arizona, Phoenix, Arizona, USA.
Salzberg D; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
Campbell C; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
Beebe K; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.; Mayo Clinic Arizona, Phoenix, Arizona, USA.
Schwalbach C; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
Magee K; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
Adams RH; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.; Mayo Clinic Arizona, Phoenix, Arizona, USA.
Ngwube A; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.; Mayo Clinic Arizona, Phoenix, Arizona, USA.
Pokaż więcej
Źródło:
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 Mar; Vol. 38 (2), pp. 154-160. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*therapy
Lymphocyte Transfusion/*methods
Transplantation Conditioning/*methods
Adolescent ; Antimetabolites, Antineoplastic/pharmacology ; Azacitidine/pharmacology ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Structure of macrophage migration inhibitory factor in complex with methotrexate.
Autorzy:
Fukushima K; Pharmaceutical Discovery Research Laboratories, Teijin Institute for Bio-Medical Research, 4-3-2 Asahigaoka, Hino-shi, Tokyo 191-8512, Japan.
Furuya M; Pharmaceutical Discovery Research Laboratories, Teijin Institute for Bio-Medical Research, 4-3-2 Asahigaoka, Hino-shi, Tokyo 191-8512, Japan.
Kamimura T; Veritas In Silico Inc., 1-11-1 Nishigotanda, Shinagawa, Tokyo 141-0031, Japan.
Takimoto-Kamimura M; Pharmaceutical Discovery Research Laboratories, Teijin Institute for Bio-Medical Research, 4-3-2 Asahigaoka, Hino-shi, Tokyo 191-8512, Japan.
Pokaż więcej
Źródło:
Acta crystallographica. Section D, Structural biology [Acta Crystallogr D Struct Biol] 2021 Mar 01; Vol. 77 (Pt 3), pp. 293-299. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*chemistry
Antirheumatic Agents/*chemistry
Intramolecular Oxidoreductases/*chemistry
Macrophage Migration-Inhibitory Factors/*chemistry
Methotrexate/*chemistry
Antimetabolites, Antineoplastic/metabolism ; Antirheumatic Agents/metabolism ; Crystallography, X-Ray ; Humans ; Methotrexate/metabolism ; Models, Molecular ; Tetrahydrofolate Dehydrogenase/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
In Vitro and In Vivo Efficacy of a Novel Glucose-Methotrexate Conjugate in Targeted Cancer Treatment.
Autorzy:
Woźniak M; Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Pastuch-Gawołek G; Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty of Chemistry, 44-100 Gliwice, Poland.; Biotechnology Centre, Silesian University of Technology, 44-100 Gliwice, Poland.
Makuch S; Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Wiśniewski J; Department of Medical Biochemistry, Wroclaw Medical University, 50-367 Wroclaw, Poland.; Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Krenács T; Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.
Hamar P; Institute of Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
Gamian A; Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Szeja W; Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty of Chemistry, 44-100 Gliwice, Poland.
Szkudlarek D; Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Krawczyk M; Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty of Chemistry, 44-100 Gliwice, Poland.; Biotechnology Centre, Silesian University of Technology, 44-100 Gliwice, Poland.
Agrawal S; Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland.; Department and Clinic of Internal Medicine, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 09; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*administration & dosage
Breast Neoplasms/*drug therapy
Drug Carriers/*chemistry
Glucose/*chemistry
Methotrexate/*administration & dosage
Animals ; Antimetabolites, Antineoplastic/pharmacokinetics ; Breast Neoplasms/pathology ; Cell Line, Tumor/transplantation ; Disease Models, Animal ; Drug Liberation/drug effects ; Drug Screening Assays, Antitumor ; Female ; Folic Acid/biosynthesis ; Glucose Transporter Type 1/antagonists & inhibitors ; Glucose Transporter Type 1/metabolism ; Humans ; Injections, Intravenous ; Methotrexate/pharmacokinetics ; Mice
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Antivitamins B 12 -Some Inaugural Milestones.
Autorzy:
Kräutler B; Institute of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, 6020, Innsbruck, Austria.
Pokaż więcej
Źródło:
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2020 Dec 01; Vol. 26 (67), pp. 15438-15445. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antimetabolites*/chemistry
Antimetabolites*/pharmacology
Vitamin B 12*/antagonists & inhibitors
Vitamin B 12*/chemistry
Animals ; Humans ; Neoplasms/drug therapy ; Vitamins/antagonists & inhibitors ; Vitamins/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Autorzy:
Van Nuland M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Thijssen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Burgers JA; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University, the Netherlands.
Marchetti S; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Schellens JHM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Nov; Vol. 9 (8), pp. 929-937. Date of Electronic Publication: 2020 Jan 22.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article
MeSH Terms:
Dose-Response Relationship, Drug*
Antimetabolites, Antineoplastic/*pharmacokinetics
Chromatography, Liquid/*methods
Deoxycytidine/*analogs & derivatives
Mass Spectrometry/*instrumentation
Administration, Intravenous ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/blood ; Antimetabolites, Antineoplastic/therapeutic use ; Area Under Curve ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Deoxycytidine/administration & dosage ; Deoxycytidine/blood ; Deoxycytidine/pharmacokinetics ; Deoxycytidine/therapeutic use ; Female ; Humans ; Male ; Mesothelioma/drug therapy ; Middle Aged ; Pilot Projects ; Predictive Value of Tests ; Prospective Studies ; Thymoma/drug therapy ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ginseng-containing traditional medicine preparations in combination with fluoropyrimidine-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis.
Autorzy:
Hu J; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Cheng M; The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Li Y; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Shi B; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
He S; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Yao Z; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Jiang J; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yu H; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
He Z; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zhao Y; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Zheng H; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Hua B; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liu R; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Apr 17; Vol. 18 (4), pp. e0284398. Date of Electronic Publication: 2023 Apr 17 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/etiology
Panax*
Humans ; Antimetabolites ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Medicine, Traditional
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.
Autorzy:
Wu X; Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.
Jiao Z; State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China. jiao_.
Zhang J; State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.
Li F; State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.
Li Y; Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2023 Apr 11; Vol. 21 (1), pp. 126. Date of Electronic Publication: 2023 Apr 11.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Animals ; Mice ; Antimetabolites, Antineoplastic ; Cytarabine/therapeutic use ; Receptors, Transferrin/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Autorzy:
Kanai M; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kawaguchi T; Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kotaka M; Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
Manaka D; Department of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, Kyoto, Japan.
Hasegawa J; Department of Surgery, Osaka Rosai Hospital, Osaka, Japan.
Takagane A; Department of Surgery, Hakodate Goryoukaku Hospital, Hakodate, Japan.
Munemoto Y; Department of Surgery, Fukui Ken Saiseikai Hospital, Fukui, Japan.
Kato T; Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Eto T; Department of Gastroenterology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
Touyama T; Department of Surgery, Nakagami Hospital, Okinawa, Japan.
Matsui T; Department of Gastroenterological Surgery, Aichi Cancer Center Aichi Hospital, Okazaki, Japan.
Shinozaki K; Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Matsumoto S; Department of Real World Data Research and Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Mizushima T; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Mori M; Tokai University School of Medicine, Isehara, Japan.
Sakamoto J; Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan.; Tokai Central Hospital, Kakamigahara, Japan.
Ohtsu A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Saji S; Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan.
Matsuda F; Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (7), pp. 7808-7814. Date of Electronic Publication: 2022 Dec 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Dihydrouracil Dehydrogenase (NADP)*/genetics
Fluorouracil*/adverse effects
Humans ; Genome-Wide Association Study ; Genotype ; Antimetabolites, Antineoplastic/adverse effects ; Capecitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Autorzy:
Tian W; Department of Oncology III, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Zhang L; Department of Nursing, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Liu X; Department of Oncology III, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Ma X; Department of Internal Medicine, Zhangqiu People's Hospital, Zhangqiu, Shandong, People' Republic of China.
Wang R; Department of Oncology III, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Mar 02; Vol. 18 (3), pp. e0282360. Date of Electronic Publication: 2023 Mar 02 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Humans ; Randomized Controlled Trials as Topic ; Antimetabolites ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Autorzy:
Feld J; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tremblay D; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Navada SC; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Silverman LR; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 525-539. Date of Electronic Publication: 2022 Nov 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/pathology
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Decitabine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients.
Autorzy:
Wang W; Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 S. Yishan Road, Shanghai, 200233, China.
Yu X; Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 S. Yishan Road, Shanghai, 200233, China.
Li H; Department of Pancreatic Surgery, Huashan Hospital, Fudan University, 12 S. Middle Urumqi Road, Shanghai, 200040, China.
Yang C; Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 S. Yishan Road, Shanghai, 200233, China.
Jin C; Department of Pancreatic Surgery, Huashan Hospital, Fudan University, 12 S. Middle Urumqi Road, Shanghai, 200040, China. .
Huang X; Department of Hepatobiliary and Pancreatic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 S. Yishan Road, Shanghai, 200233, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2023 Feb 08; Vol. 23 (1), pp. 35. Date of Electronic Publication: 2023 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/surgery
Pancreatic Neoplasms*/pathology
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/surgery
Humans ; Gemcitabine ; Deoxycytidine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Chemotherapy, Adjuvant ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.
Autorzy:
Schulte RR; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Choi L; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Utreja N; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Van Driest SL; Department of Pediatrics, Division of General Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Stein CM; Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ho RH; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2021 Jan; Vol. 14 (1), pp. 343-353. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji:
Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic/*pharmacokinetics
Leukemia, Lymphoid/*drug therapy
Liver-Specific Organic Anion Transporter 1/*genetics
Methotrexate/*pharmacokinetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Adolescent ; Adult ; Antimetabolites, Antineoplastic/administration & dosage ; Body Weight ; Child ; Child, Preschool ; Dose-Response Relationship, Drug ; Female ; Humans ; Infant ; Leukemia, Lymphoid/blood ; Male ; Methotrexate/administration & dosage ; Models, Biological ; Pharmacogenomic Testing/statistics & numerical data ; Pharmacogenomic Variants ; Polymorphism, Single Nucleotide ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Autorzy:
Kitagawa K; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Moriya K; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Kaji K; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Saikawa S; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Sato S; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Nishimura N; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Namisaki T; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Akahane T; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Mitoro A; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Yoshiji H; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 14; Vol. 21 (20). Date of Electronic Publication: 2020 Oct 14.
Typ publikacji:
Journal Article
MeSH Terms:
Anticholesteremic Agents/*pharmacology
Antimetabolites, Antineoplastic/*pharmacology
Atorvastatin/*pharmacology
Bile Duct Neoplasms/*drug therapy
Cholangiocarcinoma/*drug therapy
Deoxycytidine/*analogs & derivatives
Proto-Oncogene Proteins c-yes/*metabolism
Animals ; Anticholesteremic Agents/administration & dosage ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; Apoptosis/drug effects ; Atorvastatin/administration & dosage ; Bile Duct Neoplasms/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cholangiocarcinoma/metabolism ; Connective Tissue Growth Factor/genetics ; Connective Tissue Growth Factor/metabolism ; Contractile Proteins/genetics ; Contractile Proteins/metabolism ; Cysteine-Rich Protein 61/genetics ; Cysteine-Rich Protein 61/metabolism ; Deoxycytidine/administration & dosage ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Combinations ; Drug Interactions ; Humans ; Intercellular Signaling Peptides and Proteins/genetics ; Intercellular Signaling Peptides and Proteins/metabolism ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Muscle Proteins/genetics ; Muscle Proteins/metabolism ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
DNA Methylation as a Therapeutic Target for Bladder Cancer.
Autorzy:
Nunes SP; Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal.; Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.; Biomedical Research Institute I+12, University Hospital '12 de Octubre', 28041 Madrid, Spain.
Henrique R; Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal.; Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal.; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal.
Jerónimo C; Cancer Biology & Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal.; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar-University of Porto (ICBAS-UP), 4050-313 Porto, Portugal.
Paramio JM; Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.; Biomedical Research Institute I+12, University Hospital '12 de Octubre', 28041 Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Pokaż więcej
Źródło:
Cells [Cells] 2020 Aug 07; Vol. 9 (8). Date of Electronic Publication: 2020 Aug 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Antimetabolites, Antineoplastic*/pharmacology
Antimetabolites, Antineoplastic*/therapeutic use
Azacitidine*/pharmacology
Azacitidine*/therapeutic use
Decitabine*/pharmacology
Decitabine*/therapeutic use
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/metabolism
DNA Methylation/*drug effects
Epigenesis, Genetic/*drug effects
Animals ; Cell Line, Tumor ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.
Autorzy:
Takahashi R; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan. .
Ijichi H; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Sano M; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.; Division of Medical Research Planning and Development, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan.
Miyabayashi K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Mohri D; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Kim J; Division of Medical Research Planning and Development, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan.
Kimura G; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Nakatsuka T; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Fujiwara H; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yamamoto K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Kudo Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Tanaka Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Tateishi K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Nakai Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Morishita Y; Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Soma K; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takeda N; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, 329-0498, Japan.
Moses HL; Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University, 691 Preston Building, Nashville, TN, 37232, USA.
Isayama H; Department of Gastroenterology, Juntendo University School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
Koike K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Dec 03; Vol. 10 (1), pp. 21194. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic/*pharmacology
Deoxycytidine/*analogs & derivatives
Drug Resistance, Neoplasm/*physiology
Macrophages/*pathology
Pancreatic Neoplasms/*pathology
Vascular Cell Adhesion Molecule-1/*physiology
Animals ; Antimetabolites, Antineoplastic/therapeutic use ; Biomarkers, Tumor/blood ; Cell Line, Tumor ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Humans ; Mice ; Pancreatic Neoplasms/drug therapy ; Prognosis ; Vascular Cell Adhesion Molecule-1/blood ; Xenograft Model Antitumor Assays ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis.
Autorzy:
Taubmann J; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Krishnacoumar B; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Böhm C; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Faas M; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Müller DIH; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Adam S; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Stoll C; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Böttcher M; Department of Internal Medicine 5, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Mougiakakos D; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.; Department of Internal Medicine 5, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Sonnewald U; Division of Biochemistry, Department of Biology, University of Erlangen-Nuremberg, Erlangen, Germany.
Hofmann J; Division of Biochemistry, Department of Biology, University of Erlangen-Nuremberg, Erlangen, Germany.
Schett G; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Krönke G; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany. .; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. .
Scholtysek C; Department of Internal Medicine 3, Friedrich Alexander University of Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany. .; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Dec 03; Vol. 10 (1), pp. 21020. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glycolysis*
Antimetabolites/*pharmacology
Bone Resorption/*metabolism
Deoxyglucose/*pharmacology
Osteoclasts/*metabolism
Osteoporosis/*metabolism
Animals ; Antimetabolites/therapeutic use ; Bone Resorption/drug therapy ; Cells, Cultured ; Deoxyglucose/therapeutic use ; Female ; Lactic Acid/metabolism ; Mice ; Mice, Inbred C57BL ; Osteoclasts/drug effects ; Osteoporosis/drug therapy ; Oxygen/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 61-80 z 7517

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies